Presentation

Company Profile
Based on its proprietary immunomodulatory enzyme technology platform, Hansa Biopharma develops treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients. It also has potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase has received conditional marketing authorization by the EMA. Hansa is based in Lund, Sweden, and has operations in Europe and the US.

Recent highlights
In the first half of 2021, Hansa\s focus has been to progress with the commercial launch activities for Idefirix. In June 2021 the company announced that the Swedish New Therapies Council recommended the use of Idefirix® as desensitization treatment for highly sensitized kidney transplant patients. On the same month, the company announced the design of the U.S. trial of imlifidase in highly sensitized kidney transplant patients, following US FDA interactions. In August 2021, the company announced the reimbursement of Idefirix in the Netherlands as desensitization treatment for highly sensitized kidney transplant patients.

Outlook
In the short- to mid-term, Hansa’s focus lies into the commercial expansion of Idefirix across Europe targeting profitability. Furthermore, the company continues to pursue the kidney transplantation indication for the US market, and accelerate advancements in new therapeutic areas.